Why
Zeal Oncology® draws intrinsic value from exploring and better understanding the cancer therapeutics space. We recognize the depth and breadth of this field and take steps daily to expand our knowledge – committed to a long-term approach. Motivated by the vast unknown, we do not shy away from identifying and addressing the largest undefined areas in oncology. We’re fueled by a curious commitment to discover what’s possible – reclaiming the unknown from the unknowable. Through this journey, we understand teaching to be a key step in pursuing excellence and honing our expertise. This company was created to enrich our clients' pursuits by sharing what we’ve learned. Facilitating our clients’ missions and simultaneously fulfilling our own!
Venture capital serves an important role in both nurturing new ideas/companies and accelerating the go-to-market strategies of established assets. We recognize the asymmetric scientific, societal, and commercial upsides of advancing novel platforms and therapeutics. However, novelty is contextual. By providing venture capital firms with total vision of the cancer therapeutics space, they’re better positioned to ensure the right investments are made to bring paradigm-shifting therapies forward.
How
Zeal Oncology® designs, builds, and maintains custom databases spanning all facets of cancer therapeutics. Working from primary sources, with a discerning eye for detail, we strive to address the largest unknowns in cancer by continually refining our understanding. We begin by defining the scope of an area of oncology before compiling and synthesizing a new technical archive. Planning then executing.
We coordinate with our clients to address their unique situations before initiating knowledge transfers that arrive at their exact solution. Just as we do scientifically, we strive to understand the entirety of our clients’ challenges, only then formulating and delivering the most impactful solution. When clients’ goals reside outside of our areas of operation, we work to connect them with the external resources best suited for their needs. We value you achieving your exact solution even if that means us not formally engaging this time around.
What
Build then Deliver
Build
We conceptualize, construct, and maintain custom databases pertaining to the cancer therapeutics space. Each database is purpose-built from the ground up to alleviate scientific pain points faced by venture capital firms. Our foundational work contains 5,800+ active human cancer therapeutic assets being developed globally across 2,490+ companies. Currently, the companies and assets are defined across 35 metrics most pertinent to discerning their novelty and commercial promise. We are positioned to expand current databases and create new databases to meet client needs. Contact us below to present the challenges you face and discuss how together we can achieve an exact solution.
Deliver
We use our backend databases to address bespoke client inquiries. We use discrete information dissemination to arrive at custom implementable solutions. All client-facing work is completed by the individual who built the databases, ensuring the highest level of data familiarity. We specialize in helping venture capital firms understand the novelty of companies, approaches, assets, and opportunities.
Engage